Effects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma
|
|
- Sabina Dean
- 5 years ago
- Views:
Transcription
1 Effects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma RUTH E. ALDRIDGE, ROBERT J. HANCOX, D. ROBIN TAYLOR, JAN O. COWAN, MARTI C. WINN, CHRIS M. FRAMPTON, and G. IAN TOWN Canterbury and Otago Respiratory Research Groups, Christchurch and Dunedin Schools of Medicine, University of Otago, Christchurch, New Zealand Previous studies have shown that the regular administration of short acting -agonists can be associated with adverse effects on airway caliber and bronchial hyperresponsiveness (BHR) and that this may occur through a proinflammatory mechanism. The aim was to explore possible adverse effects of high-dose -agonist therapy and to assess any adverse interaction with corticosteroids. We undertook a randomized, crossover study to investigate the effects of 6 wk of treatment with regular terbutaline (1 mg four times a day), regular budesonide (400 g twice a day), combined treatment, and placebo in subjects with mild to moderate asthma. Major endpoints were PD 15 saline, PD 20 methacholine, and induced sputum differential cell counts. Thirty-four subjects were randomized and 28 completed the study. PD 15 saline decreased on terbutaline alone compared with placebo treatment and on combined treatment compared with budesonide alone (mean fold decrease of 0.57 [95% CI 0.36, 0.90] and 0.65 [95% CI 0.43, 0.97], respectively). PD 20 methacholine was not affected by the use of terbutaline either alone or in combination with budesonide. The percentage of eosinophils in induced sputum increased during terbutaline treatment alone compared with placebo (median 8.3% versus 4.4%, p 0.049). The addition of terbutaline to budesonide did not affect the percentage of eosinophils compared with budesonide treatment alone. These findings support the hypothesis that short-acting -agonists have a permissive effect on airway inflammation and that when used in high dose there may be an unfavorable interaction with inhaled corticosteroids. Inhaled corticosteroids and short-acting -agonists are very widely used in the treatment of patients with asthma. The beneficial effects of corticosteroids, which include improvement in airway caliber, bronchial hyperresponsiveness (BHR), and airway inflammation, are well documented (1). Although shortacting -agonists are undoubtedly safe when used as required for the relief of acute symptoms, their regular use has been shown to have adverse effects (2). Continuous use of shortacting -agonist has been associated with deleterious effects on peak expiratory flow rates (PEFR), spirometric values, and BHR to methacholine, histamine, and allergen (3, 4). The clinical significance of these effects has been widely debated (3, 5). The adverse changes in BHR have been more readily demonstrated when bronchoconstriction involves indirect cellular mechanisms (adenosine monophosphate [AMP], allergen) rather than stimulation of smooth muscle directly (histamine, methacholine) (6 10). These findings have generated the hypothesis (Received in original form June 11, 1999 and in revised form October 5, 1999) The study was funded by an Otago Research Grant. Dr Aldridge and Dr. Hancox were supported by an educational grant from GlaxoWellcome NZ Ltd. Astra Draco supplied the study medication and matching placebos. Ipratropium bromide was supplied by Boehringer Ingelheim, Germany. Correspondence and requests for reprints should be addressed to Dr. G. I. Town, Christchurch School of Medicine, P.O. Box 4345, Christchurch, New Zealand. ian.town@chmeds.ac.nz Am J Respir Crit Care Med Vol 161. pp , 2000 Internet address: that the regular administration of short-acting -agonist may have a permissive effect on underlying airway inflammation (4). The effects of regular short-acting -agonist on airway inflammation have only been investigated in three studies to our knowledge. In one study, an increase in the total number of eosinophils and their activation status in bronchial biopsies was demonstrated (11). In another, no change in bronchoalveolar lavage cell count or eosinophil cationic protein level (12) was observed. In contrast, in a third study short-acting -agonist treatment resulted in a reduction in lymphocyte number with no change in eosinophil numbers in bronchial biopsies (13). The combination of short-acting -agonist with inhaled corticosteroid has not been extensively investigated; however, there is some evidence to suggest that -agonists may impair the anti-inflammatory effects of corticosteroids (8, 14, 15). Clinical interactions between short-acting -agonists and corticosteroids have recently been studied by our group (16). We found that morning PEFR, FEV 1, and BHR to methacholine were improved with corticosteroid, and that the addition of regular terbutaline improved clinical indices. This new study was designed to extend our observations on the effect of combining short-acting -agonists with corticosteroids, particularly in light of the proposed negative interaction between these two drugs at a molecular level (14). We wished to examine the effects of short-acting -agonists and corticosteroids on inflammatory indices in induced sputum, and to compare the effect of treatment on BHR to hypertonic saline and methacholine. We hypothesized that regular shortacting -agonist treatment would be associated with increased airway inflammation and that any such adverse effects would be more readily detected by assessing BHR to hypertonic saline (indirect cellular mechanism) than to methacholine (direct smooth muscle mechanism). METHODS Subjects Subjects age 16 to 64 yr with mild to moderate asthma for more than 1 yr were recruited. All subjects were atopic (positive skin test to Dermatophagoides pteronyssinus, mixed grass pollen, or cat pelt), and demonstrated BHR to methacholine (provocative dose causing a 20% fall in FEV 1 [PD 20 ] or provocative concentration causing a 20% fall in FEV 1 [PC 20 ] 8 mol or 12 mol if taking inhaled corticosteroid), but had an FEV 1 50% predicted. They also needed to be able to produce sputum after induction with 4.5% hypertonic saline. Subjects were excluded if they had any other serious concurrent medical illness, if they had a smoking history of more than 5 pack-years, or if they had smoked tobacco in the preceding year. Subjects taking more than 1,500 g of inhaled corticosteroid per day, or who had required oral corticosteroids during the previous 3 mo, were also excluded. All subjects gave written informed consent and the study was approved by the Canterbury and Otago Ethics Committees. Study Design This was a randomized, double-blind, placebo-controlled, doubledummy, crossover study. During a prerandomization run-in period, all asthma medications were withdrawn except short-acting bron-
2 1460 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL chodilators, together with any intranasal corticosteroid treatment. For the following 4 wk subjects recorded their peak flow rates and symptoms twice daily in a diary. Provided they did not become clinically unstable, subjects were then randomized to receive the following treatments, each for 6 wk: (1) terbutaline Turbuhaler 500 g 2 puffs four times a day and placebo Turbuhaler 1 puff twice a day; (2) placebo Turbuhaler 2 puffs four times a day and budesonide Turbuhaler 400 g 1 puff twice a day; (3) terbutaline Turbuhaler 500 g 2 puffs four times a day and budesonide Turbuhaler 400 g 1 puff twice a day; (4) placebo Turbuhaler 2 puffs four times a day and placebo Turbuhaler 1 puff twice a day. The trial medication and matching placebos were supplied by Astra Draco, Lund, Sweden. During the treatment periods, subjects were instructed to use ipratropium bromide 40 g via metered-dose inhaler (Boehringer Ingelheim, Germany) for relief of symptoms but no other asthma medication was permitted except in the event of a severe asthma attack. At the end of each 6-wk period, subjects underwent a combined hypertonic saline challenge/sputum induction procedure. Three to 7 d later, they underwent a methacholine challenge test. At this visit, study medication for the next period was issued to the subjects. Whenever possible, the challenge tests were performed at the same time of day. Study medication and ipratropium were withheld either overnight (for subjects whose challenge tests were conducted in the morning), or for at least 6 h before each challenge test performed late in the day. Subjects were monitored closely throughout the study and had 24-h access to a medical investigator together with an emergency supply of prednisone tablets and a salbutamol inhaler. In the event of a subject experiencing an exacerbation sufficiently severe to warrant additional treatment, they were temporarily withdrawn from the study. Thereafter, if considered clinically appropriate, subjects were reentered into the next treatment period once their asthma had restabilized. Subjects had to have discontinued oral and inhaled corticosteroids for at least 4 wk before they could rejoin the study. Treatment periods interrupted by asthma exacerbations were not repeated. Measurements Airway caliber. PEFR were measured twice daily using a mini-wright peak flow meter (Clement Clarke Int. Ltd, Harlow, UK) as the highest of three values taken prior to morning and evening study medication. FEV 1 was measured using a rolling seal spirometer (Spirotech; Graseby, Smyrna, GA) and was taken as the highest of three reproducible maneuvers recorded at the end of each treatment period immediately before the saline challenge. Symptom diary. The following daytime symptoms were documented daily in a diary on a score of 0 to 3: wheeze, breathlessness on activity, cough, and sputum production. Similarly nighttime symptoms of nocturnal wakening, wheeze, and cough were recorded. The use of ipratropium was recorded twice daily. Hypertonic saline challenge/sputum induction procedure. Baseline FEV 1 was recorded. Nebulized 4.5% saline was generated from an ultrasonic nebulizer (Ultra-Neb 2000; DeVilbiss, Somerset, PA) using large bore tubing, a large two-way nonrebreathing valve (2700; Hans Rudolph Inc., Kansas City, MO) and rubber mouthpiece (mean nebulizer output to subjects 1.6 ml/min). The saline was inhaled for the following time periods: 0.5, 0.5, 1, 2, 4, 4, 4, 4 min (modified version of Iredale and coworkers [17]). FEV 1 was measured 1 min after each period of inhalation. Between each inhalation period, subjects rinsed their mouth with water and were encouraged to cough sputum into a plastic container. The challenge procedure was stopped if the FEV 1 fell more than 20% from baseline, and subjects were given salbutamol 200 g from a metered-dose inhaler via spacer. Spirometry was repeated after 5 min. At this point the inhalation regimen was restarted in order to collect more sputum, provided the subject s FEV 1 was greater than 90% of baseline value. The procedure was stopped after 20 min or after an adequate sputum sample had been obtained. The nebulizer output was calculated by weighing the nebulizer canister before and immediately after the challenge test. The cumulative dose of saline causing a 15% decrease in FEV 1 (PD 15 saline) was calculated by linear interpolation on the log dose response plot. Methacholine challenge test. BHR to methacholine was measured using a modified version of the rapid challenge procedure (18). After measurement of the baseline FEV 1, subjects inhaled nebulized 0.9% saline as a control, followed by a series of doubling doses of methacholine (0.044 to 44 mol taken in one or two breaths), from a Nebicheck dosimeter (P.K. Morgan Ltd, Gillingham, Kent, UK). FEV 1 was measured 1 min after each dose, and immediately after this the subjects inhaled the next dose of methacholine. The test was stopped when the FEV 1 had fallen by greater than 20% from the postsaline value or when the highest dose had been administered. The cumulative provocation dose of methacholine causing a 20% reduction in FEV 1 (PD 20 methacholine) was calculated by linear interpolation between the last two readings on the log dose response plot. Sputum processing and analysis. The entire expectorated sample was homogenized by the addition of 1% dithiothreitol (the volume of 1% dithiothreitol added equating to 3 times the weight of the sputum sample) (Sputolysin; Calbiochem, La Jolla, CA) (19). The mixture was then placed in a rocking waterbath at 37 C for 30 min to ensure complete dispersion before being filtered through a 48- m nylon mesh (B&SH Thompson, Mississauga, ON, Canada). The total cell count, percentage squamous cells, and percentage cell viability (trypan blue exclusion) were determined using a hemocytometer. An aliquot was diluted to obtain a concentration of approximately cells/ml from which cytospins were prepared (Shandon 2; Shandon Southern Products Ltd, Runcorn, Cheshire, UK). The remaining sputum mixture was centrifuged at 1,350 g for 5 min, the supernatant decanted and frozen at 80 C for future analysis. Sputum cell counts. Cytospins were stained with May Grunwald Giemsa and a 400 differential cell count (excluding squamous cells) was determined in duplicate. Statistical Analysis Results were analyzed for all subjects who completed two or more treatment periods (n 28). Diary data from the first 2 wk of each treatment period were excluded to minimize the influence of any carry-over effect and to remove the need for a washout period. Each symptom was analyzed as the percentage of symptomatic days or nights reported during the treatment period. Similarly, the use of ipratropium was analyzed as the percentage of days and nights during which it was taken. Normally distributed data (FEV 1, PEFR, log PD 15 saline, and log PD 20 methacholine) were initially assessed for an overall treatment effect using a general linear model repeated-measures analysis. If a significant treatment effect was revealed, further analysis of each of the six pairwise comparisons using the paired t test was undertaken. Nonparametric data (percentage of days with each symptom and in which ipratropium was used and the percentages of each cell type in sputum) were initially assessed with Friedman s test, and if appropriate, analyzed in pairs using the Wilcoxon signed-rank test. A p value of 0.05 was considered statistically significant. Parametric data are plotted as the mean with the least significant difference, nonparametric data as the median with the interquartile range. All statistical tests were performed using SPSS version 8.0 software (SPSS Inc., Chicago, IL). RESULTS Fifty-two subjects were initially recruited to the study. Eighteen of these were withdrawn before randomization because of deteriorating asthma (11), the inability to produce sputum (4), social reasons (2), or because a PD 20 methacholine was not achieved (1). The clinical characteristics of the 34 randomized subjects are shown in Table 1. Of these, 28 (82%) completed the study, with four subjects withdrawn on account of poor asthma control and two for social reasons. As these subjects all withdrew during the first or second treatment periods, treatment comparisons were only performed on the 28 remaining subjects. During the study proper, six exacerbations occurred in five of the 28 subjects. Three of these occurred in the terbutaline alone treatment period, and three in the placebo period. One subject withdrew in the placebo period after completing the saline challenge test but before the methacholine challenge was performed.
3 Aldridge, Hancox, Taylor, et al.: -Agonist Therapy and Airway Inflammation 1461 PEFR TABLE 1 BASELINE CLINICAL CHARACTERISTICS (n 34) Age, mean, yr 39 (range 18 61) Sex, male:female 18:16 Inhaled corticosteroids* at entry None 12 (35.0%) g/d 8 (23.5%) g/d 8 (23.5%) 501 1,000 g/d 6 (18.0%) FEV 1, mean, L 3.05 (95% CI ) FEV 1, % predicted, mean 89.5 (95% CI ) * Beclomethasone and budesonide regarded as equivalent. Analysis of the PEFR data on a week-by-week basis revealed no time trends. Morning PEFR (Table 2 and Figure 1) was significantly higher on budesonide than on terbutaline or placebo treatment ( 19 L/min, p and 17 L/min, p 0.001, respectively). Morning PEFR was further increased on combined treatment compared with budesonide alone ( 22 L/min, p 0.001). There was no significant difference in morning PEFR between terbutaline and placebo. Evening PEFR (Table 2) was significantly higher on budesonide compared with placebo treatment ( 15 L/min, p 0.005), and significantly higher on terbutaline versus placebo treatment ( 30 L/min, p 0.001). There was no significant difference in evening PEFR between budesonide and terbutaline. Combined treatment resulted in a higher evening PEFR than any of the other treatments (p 0.001). Symptoms and Rescue Medication Use Analysis of the diary data on a week-by-week basis revealed no time trends. No significant treatment effects were seen for nighttime wakening, cough, sputum production, or breathlessness on activity. The percentage of days and nights with wheeze decreased on budesonide treatment, when given alone or in combination with terbutaline (Table 2). The addition of terbutaline to placebo or budesonide did not result in any significant changes. The percentage of days on which ipratropium was used fell for all three treatments compared with placebo (p 0.04). FEV 1 FEV 1 data are shown in Table 2 and Figure 2. FEV 1 was higher on budesonide treatment compared with terbutaline or placebo treatment ( 0.31 L, p 0.001, and 0.26 L, p 0.002, respectively). Similarly, FEV 1 was higher on the combined treatment compared with terbutaline or placebo treatment alone ( 0.17 L, p 0.019, and 0.12 L, p 0.042, respectively). FEV 1 was lower on combined treatment compared with budesonide alone ( 0.14 L, p 0.030). There was a trend toward a lower FEV 1 on terbutaline compared with placebo but this did not reach statistical significance. Hypertonic Saline PD 15 A PD 15 saline was achieved in 88 (82%) of the 107 saline challenge tests conducted during the randomized periods. Linear extrapolation, equivalent to a further 4 min of saline administration, allowed an additional two cases to be included in the analysis. For the remaining challenges an arbitrary value of 30 ml ( maximal calculated PD 15 value) was assigned. PD 15 saline data are shown in Table 2 and Figure 3. PD 15 saline was higher on budesonide treatment compared with terbutaline or placebo treatment: 3.99-fold increase (95% confidence interval [CI] 2.32, 6.88) and 2.32 (95% CI 1.48, 3.63), respectively. PD 15 saline was lower on terbutaline compared with TABLE 2 EFFECT OF ALL FOUR TREATMENT GROUPS ON OUTCOME MEASURES (n 24 28)* Treatment Treatment Effects (p Value) P T B C P versus T P versus B P versus C T versus B T versus C B versus C Morning PEFR, L/min Evening PEFR, L/min Daytime wheeze, % days present Nighttime wheeze, % nights present Daytime ipratropium use, % days used FEV 1, L PD 15, saline, ml PD 20 methacholine, mol Sputum % eosinophils Sputum % neutrophils No significant treatment effect Sputum % lymphocytes No significant treatment effect Sputum % macrophages No significant treatment effect Sputum % epithelial cells No significant treatment effect Definition of abbreviations: B budesonide; C combined treatment; P placebo; T terbutaline. * PEFR, FEV 1 data displayed as mean and 95% CI. PD 15 saline and PD 20 methacholine data displayed as geometric mean and 95% CI. Sputum % cells, wheeze, and ipratropium use data displayed as median and interquartile range.
4 1462 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Figure 1. Treatment effects for morning PEFR. Data are displayed as mean (square symbol) with error bars representing the least significant difference at the 5% level. Figure 3. Treatment effects for PD 15 saline. Data are displayed as geometric mean (square symbol) with error bars representing the least significant difference at the 5% level. placebo treatment and on combined treatment versus budesonide alone (0.57-fold decrease [95% CI 0.36, 0.90] and 0.65 [95% CI 0.43, 0.97], respectively). There was no significant difference in PD 15 saline on combined treatment compared with placebo. There was no relationship between changes in FEV 1 and changes in BHR to saline in any of the treatment groups (data not shown). Methacholine PD 20 A PD 20 methacholine was achieved in 103 (97%) of the 106 methacholine challenge tests conducted during the randomized periods. For the three remaining challenge tests an arbitrary value of 54 mol ( maximal calculated PD 20 value) was assigned. PD 20 methacholine data are shown in Table 2 and Figure 4. PD 20 methacholine was higher on budesonide treatment compared with terbutaline or placebo treatment (5.08- fold increase [95% CI 2.73, 9.48] and 3.86 [95% CI 2.39, 6.22], respectively). Similarly PD 20 methacholine was higher on the combined treatment compared with terbutaline or placebo treatment (4.23-fold increase [95% CI 2.49, 7.19] and 3.31 [95% CI 2.17, 5.05], respectively). There was no significant difference in PD 20 methacholine on combined treatment versus budesonide alone, or for terbutaline compared with placebo. Sputum Differential Cell Counts Sputum quality (total cell count, percent squamous cell, percent cell viability) did not significantly differ between treatment periods (Table 3). There was a significant treatment effect for the percentage of eosinophils in sputum (Table 2, Figure 5) but not for any of the other cell types. Eosinophils were lower on budesonide treatment compared with terbutaline or placebo treatment ( 6.6%, p and 2.7%, p 0.012, respectively). The percentage of eosinophils was higher on terbutaline compared with placebo treatment ( 3.9%, p 0.049). There was no significant difference for eosinophils on combined treatment compared with budesonide alone. Figure 2. Treatment effects for FEV 1. Data are displayed as mean (square symbol) with error bars representing the least significant difference at the 5% level. Figure 4. Treatment effects for PD 20 methacholine. Data are displayed as geometric mean (square symbol) with error bars representing the least significant difference at the 5% level.
5 Aldridge, Hancox, Taylor, et al.: -Agonist Therapy and Airway Inflammation 1463 TABLE 3 SPUTUM QUALITY IN EACH OF THE FOUR TREATMENT PERIODS (n 24 28)* Treatment P T B C Total cell count, 10 9 /L ( ) ( ) ( ) ( ) Squamous cells, % ( ) ( ) ( ) ( ) Cell viability, % (74 84) (72 85) (67 84) (74 84) Definition of abbreviations: B budesonide; C combined treatment; P placebo; T terbutaline. * Data are displayed as median, with interquartile range in parentheses. DISCUSSION The results of this investigation provide additional data concerning the proinflammatory as well as the anti-inflammatory effects of the two drug therapies most commonly used in the management of chronic asthma, namely inhaled -agonists and corticosteroids. Although it is no longer recommended that short-acting -agonists be taken regularly, many patients use short-acting agents frequently in addition to their anti-inflammatory medication. For this reason investigating possible interactions between the two drugs is clinically relevant, and the design of our study reflected this objective. The principal finding was that high-dose terbutaline alone resulted in a significant increase in sputum eosinophils and BHR to saline when compared with placebo. There were no significant changes in symptoms, BHR to methacholine, morning PEFR, or FEV 1. These data indicate that when given as monotherapy in our patients, -agonist alone had a proinflammatory effect although no major impact on lung function was observed. The effects of regular short-acting -agonists on measurements of lung function and BHR to methacholine, histamine, and allergen have been reviewed previously (3), although not all published studies have reported negative effects consistently. The adverse effects of -agonist on more specific measures of airway inflammation have not been studied as extensively. The increase in sputum eosinophils seen in the present study is in keeping with the results of a previous investigation in which an increase in both the total number of eosinophils and their activation status was observed with regular shortacting -agonist (11). Similarly, short-acting -agonist has been shown to augment the increase in sputum eosinophils and eosinophilic cationic protein observed after allergen challenge (20). Moreover, the administration of regular short-acting -agonist to subjects with an early asthmatic response to allergen has been shown to increase the likelihood of developing a dual asthmatic response, suggesting a proinflammatory action (21). In vitro, exposure of blood eosinophils to short-acting -agonist resulted in a dose-dependent increase in their respiratory burst, suggesting that short-acting -agonists may affect eosinophil activation status directly (22). Terbutaline treatment resulted in increased BHR to saline but not to methacholine. A similar difference between saline and methacholine has been observed previously in a study which examined the effects of regular inhaled salbutamol in nonasthmatic atopic subjects (23). Short-acting -agonists have been shown to have a greater effect on BHR when the mechanism of induced bronchoconstriction involves indirect pathways such as allergen rather than direct stimulation of bronchial smooth muscle (6 10). Moreover, the loss of the acute protective effect of short-acting -agonists during regular treatment is more obvious using indirect provocation stimuli such as AMP, than with directly acting nonspecific stimuli such as methacholine (6). Hypertonic saline is thought to cause bronchoconstriction via indirect cellular mechanisms, notably stimulation of mast cells and local sensory nerves (24). Our data suggest that saline challenge may be a more sensitive measurement of airway inflammation. Our study was also designed to test the hypothesis that the benefits of inhaled corticosteroid might be compromised when inhaled -agonist was given in combination. When given as monotherapy, budesonide treatment resulted in a reduction in sputum eosinophils, a reduction in BHR to hypertonic saline and methacholine, and improved lung function. These effects are well-documented in the literature (25 28). The combination of budesonide with terbutaline, however, provided contrasting outcomes. On the one hand, there was no significant difference in sputum eosinophils with combined treatment compared with budesonide alone. On the other, combined treatment appeared to negate the improvement in BHR to saline but not to methacholine obtained with budesonide: PD 15 saline on combined treatment was not significantly different from placebo. This pattern of differential effects on BHR has been noted previously. In a crossover study in 13 asthmatics, Cockcroft and coworkers demonstrated that compared with treatment with budesonide alone, BHR to allergen but not methacholine was increased when salbutamol was simultaneously administered (8). Similarly, in a parallel group Figure 5. Treatment effect on % sputum eosinophils. Data are displayed as median with interquartile range, 10th and 90th percentiles, and outliers. * P significantly different from placebo, * T significantly different from terbutaline, * B significantly different from budesonide, * C significantly different from combined treatment, p 0.05.
6 1464 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL study of 41 patients, Wong and colleagues found that the protective effect of 2 to 4 wk treatment with budesonide against allergen challenge was reduced in patients receiving regular terbutaline (15). In our study, we also observed that FEV 1 was significantly lower on combined treatment than with budesonide alone. This pattern is different from that for mean morning PEFR, an observation which has been made previously (15, 29). The explanation for these differential effects on measurements of lung function is unclear. The clinical relevance of our findings remains uncertain. Our earlier crossover study did not reveal any adverse changes in asthma control with terbutaline treatment, either as monotherapy or in combination with budesonide (16). In fact, the combination of terbutaline and budesonide was ranked best of the four treatments using a hierarchy of relevant clinical endpoints. In this study, despite the proinflammatory effects of terbutaline, no clinically important negative effect has been identified. However, patients recruited into these two studies were necessarily required to tolerate the withdrawal of inhaled corticosteroid during the run-in period, and thus only patients with mild asthma were enrolled. It is possible that the proinflammatory actions of short-acting -agonists may counterbalance the benefits of inhaled corticosteroid treatment when subjects with more severe asthma are studied, or when different dose combinations of the two drugs are used, or when subjects are investigated over longer periods of time. This might explain the adverse effect on asthma control which has been observed in some studies despite the use of anti-inflammatory treatment (30, 31). Certainly, our observations reinforce current guidelines that short-acting agents should be used only as required, and ought to prompt clinicians to carefully review patients whose asthma is poorly controlled and whose use of -agonist as reliever is excessive. Acknowledgment: The authors thank the volunteers for participating in this study, Timothy Chan for performing the analyzis of induced sputum, and Erin Flannery and Christine McLachlan for helping with the challenge testing. References 1. Barnes, P. J Efficacy of inhaled corticosteroids in asthma. J. Allergy Clin. Immunol. 102: Sears, M. R., and D. R. Taylor The beta 2-agonist controversy: observations, explanations and relationship to asthma epidemiology. Drug Safety 11: Taylor, D. R., M. R. Sears, and D. W. Cockcroft The -agonist controversy. Med. Clin. North Am. 80: Cockcroft, D. W., and V. A. Swystun Functional antagonism: tolerance produced by inhaled beta-2 agonists. Thorax 51: Barrett, T. E., and B. L. Strom Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? Am. J. Respir. Crit. Care Med. 151: O Connor, B. J., S. L. Aikman, and P. J. Barnes Tolerance to the non-bronchodilator effects of inhaled beta 2-agonists in asthma. N. Engl. J. Med. 327: Taylor, D. A., M. W. Jensen, S. L. Aikman, J. G. Harris, P. J. Barnes, and B. J. O Connor Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am. J. Respir. Crit. Care Med. 156: Cockcroft, D. W., V. A. Swystun, and R. Bhagat Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am. J. Respir. Crit. Care Med. 152: Cockcroft, D. W., C. P. McParland, S. A. Britto, V. A. Swystun, and B. C. Rutherford Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342: Bhagat, R., V. A. Swystun, and D. W. Cockcroft Salbutamolinduced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J. Allergy Clin. Immunol. 97: Manolitsas, N. D., J. Wang, J. L. Devalia, C. J. Trigg, A. E. McAulay, and R. J. Davies Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am. J. Respir. Crit. Care Med. 151: Adelroth, E., L. Rosenhall, S. A. Johansson, M. Linden, and P. Venge Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: the effects of antiasthmatic treatment with budesonide or terbutaline. Am. Rev. Respir. Dis. 142: Laitinen, L. A., A. Laitinen, and T. Haahtela A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta-2 agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol. 90: Adcock, I. M., D. A. Stevens, P. J. Barnes Interactions of glucocorticoids and beta 2 agonists. Eur. Respir. J. 9: Wong, C. S., I. Wahedna, I. D. Pavord, and A. E. Tattersfield Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am. J. Respir. Crit. Care Med. 150: Hancox, R. J., J. O. Cowan, E. M. Flannery, G. P. Herbison, C. R. McLachlan, C. S. Wong, and D. R. Taylor A randomized trial of inhaled agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 54: Iredale, M. J., S. A. R. Wanklyn, I. P. Phillips, T. Krausz, and P. W. Ind Non-invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic saline. Clin. Exp. Allergy 24: Yan, K., C. Salome, and A. J. Woolcock Rapid method for measurement of bronchial responsiveness. Thorax 38: Fahy, J. V., J. Liu, H. Wong, and H. A. Boushey Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev. Respir. Dis. 147: Gauvreau, G. M., M. Jordana, R. M. Watson, D. W. Cockroft, P. M. O Byrne Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am. J. Respir. Crit. Care Med. 156: Lai, C. K., O. P. Twentyman, and S. T. Holgate The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am. Rev. Respir. Dis. 140: Nielson, C. P., and N. E. Hadjokas Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am. J. Respir. Crit. Care Med. 57: Evans, D. W., C. M. Salome, G. G. King, S. J. Rimmer, J. P. Seale, and A. J. Woolcock Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects. Thorax 52: Smith, C. M., and S. D. Anderson Inhalation provocation tests using nonisotonic aerosols. J. Allergy Clin. Immunol. 84: Juniper, E. F., P. A. Kline, M. A. Vanzieleghem, E. H. Ramsdale, P. M. O Byrne, and F. E. Hargreave Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis. 142: Gauvreau, G. M., J. Doctor, R. M. Watson, M. Jordana, and P. M. O Byrne Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care Med. 154: Claman, D. M., H. A. Boushey, J. Liu, H. Wong, and J. V. Fahy Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J. Allergy Clin. Immunol. 94: Djukanovic, R., J. W. Wilson, K. M. Britten, S. J. Wilson, A. F. Walls, W. R. Roche, P. H. Howarth, and S. T. Holgate Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. 145: Wilding, P. J., M. M. Clark, J. Oborne, J. A. Bennett, and A. E. Tattersfield Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 51: Sears, M. R., D. R. Taylor, C. G. Print, D. C. Lake, E. M. Flannery, M. K. Lucas, D. M. Yates, G. P. Herbison, and Q. Li Regular inhaled -agonist treatment in bronchial asthma. Lancet 336: Taylor, D. R., M. R. Sears, G. P. Herbison, E. M. Flannery, C. G. Print, D. C. Lake, D. M. Yates, M. K. Lucas, and Q. Li Regular inhaled -agonist in asthma: effects on lung function and exacerbations. Thorax 48:
Tolerance to beta-agonists during acute bronchoconstriction
Eur Respir J 1999; 14: 283±287 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Tolerance to beta-agonists during acute bronchoconstriction
More informationDifferential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma
Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma JULIA A. NIGHTINGALE, DUNCAN F. ROGERS, and PETER J. BARNES Thoracic Medicine, National Heart and Lung Institute,
More informationTime course of action of two inhaled corticosteroids, fluticasone propionate and budesonide
ASTHMA Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide K Phillips, J Oborne, S Lewis, T W Harrison, A E Tattersfield... See end of article for authors affiliations...
More informationLow- and high-dose fluticasone propionate in asthma; effects during and after treatment
Eur Respir J 2000; 15: 11±18 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Low- and high-dose fluticasone propionate in asthma; effects
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationReversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Eur Respir J 2001; 17: 368 373 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Reversing acute bronchoconstriction in asthma: the effect of
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1267 ISSN 1175 8716 Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand Catherina L Chang, Manisha Cooray, Graham Mills,
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationC linicians have long regarded asthma as a heterogeneous
875 ORIGINAL ARTICLE Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids R H Green, C E Brightling,
More informationEffect of 1 year daily treatment with 400 µg budesonide (Pulmicort Turbuhaler ) in newly diagnosed asthmatics
Eur Respir J 1997; 10: 2210 2215 DOI: 10.1183/09031936.97.10102210 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of 1 year daily
More informationTolerance to bronchodilating effects of salmeterol in COPD
Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130
More informationAn inhaled steroid improves markers of airway inflammation in patients with mild asthma
Eur Respir J 998; : 8 88 DOI:.8/996.98.8 Printed in UK - all rights reserved Copyright ERS Journals Ltd 998 European Respiratory Journal ISSN 9-96 An inhaled steroid improves markers of airway inflammation
More informationDiagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests
Diagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris McLachlan, Gabrielle Monti-Sheehan, Pamela Jackson, and
More informationComparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma
Eur Respir J 2002; 20: 66 72 DOI:.83/0903936.02.00094202 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-936 Comparison of anti-inflammatory and
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationMechanisms of action of bronchial provocation testing
Mechanisms of action of bronchial provocation testing TSANZ / ANZSRS Masterclass: April 3rd, 2016 13:00 13:30 John D. Brannan PhD Scientific Director - Dept. Respiratory & Sleep Medicine John Hunter Hospital,
More informationInduced sputum to assess airway inflammation: a study of reproducibility
Clinical and Experimental Allergy. 1997. Volume 27. pages 1138-1144 Induced sputum to assess airway inflammation: a study of reproducibility A. SPANEVELLO, G. B. MIGLIORI. A. SHARARA*, L. BALLARDlNIt,
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationDeterminants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction
Respiratory Medicine (2006) 100, 1760 1766 Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction Heikki O. Koskela a,, Vesa Kiviniemi b, Minna K. Purokivi
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationStarting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment
Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment THYS van der MOLEN, BETTY MEYBOOM-DE JONG, HELMA H. MULDER, and DIRKJE S. POSTMA Department of General Practice,
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationStrategy Aimed at Reduction of Sputum Eosinophils Decreases Exacerbation Rate in Patients with Asthma
The Journal of International Medical Research 2006; 34: 129 139 Strategy Aimed at Reduction of Sputum Eosinophils Decreases Exacerbation Rate in Patients with Asthma J CHLUMSKÝ 1, I STRIZ 2, M TERL 3 AND
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationComparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
More informationAcute Anti-inflammatory Effects of Inhaled Budesonide in Asthma A Randomized Controlled Trial
Acute Anti-inflammatory Effects of Inhaled Budesonide in Asthma A Randomized Controlled Trial PETER G. GIBSON, NICHOLAS SALTOS, and KELLIE FAKES Airway Research Centre, Department of Respiratory and Sleep
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationDoes ketotifen have a steroid-sparing effect in childhood asthma?
Eur Respir J, 1997; 1: 65 7 DOI: 1.1183/931936.97.1165 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 93-1936 Does ketotifen have a steroid-sparing
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationEffect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Eur Respir J 2001; 17: 374 379 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Effect of oral prednisolone on the bronchoprotective effect
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationAirway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma
Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma Peter G. Gibson, MBBS, FRACP, a Nicholas Saltos, MBBS, FRACP, FCCP, b
More informationUniversity of Groningen. Transdermal delivery of anticholinergic bronchodilators Bosman, Ingrid Jolanda
University of Groningen Transdermal delivery of anticholinergic bronchodilators Bosman, Ingrid Jolanda IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationMeasurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination
Eur Respir J, 1996, 9, 1174 1180 DOI: 10.1183/09031936.96.09061174 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 Measurement of inflammatory
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationInduced Sputum Inflammatory Mediator Concentrations in Eosinophilic Bronchitis and Asthma
Induced Sputum Inflammatory Mediator Concentrations in Eosinophilic Bronchitis and Asthma CHRISTOPHER E. BRIGHTLING, RICHARD WARD, GERRIT WOLTMANN, PETER BRADDING, JAMES R. SHELLER, RYSZARD DWORSKI, and
More informationTreatment of acute asthmatic exacerbations with an increased dose of inhaled steroid
12 Paediatrics and Child Health, Dunedin School of Medicine, PO Box 913, University of Otago Medical School, Dunedin, New Zealand J Garrett Preventive and Social Medicine, Dunedin School of Medicine S
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationClinical Issues Research Implemented April 2010 Asthma Major Recommendations Goals of asthma: - 1) reduction of impairment freedom from symptoms,
Asthma Major Recommendations Goals of : - 1) reduction of impairment freedom from symptoms, such as cough, shortness of breath, wheezing, and disturbed sleep minimal need (< 2 times per week) of short
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationSalmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients
Thorax 1988;43:674-678 Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients ANDERS ULLMAN, NILS SVEDMYR From the Department of Clinical
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationThe New England Journal of Medicine
A COMPARISON OF LOW-DOSE INHALED BUDESONIDE PLUS THEOPHYLLINE AND HIGH-DOSE INHALED BUDESONIDE FOR MODERATE ASTHMA DAVID J. EVANS, M.B., DAVID A. TAYLOR, M.B., OLLE ZETTERSTROM, M.D., K. FAN CHUNG, M.D.,
More informationSafety of β2-agonists in asthma
Safety of β2-agonists in asthma Sanjeeva Dissanayake IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Overview Origin of concerns Mechanistic hypotheses Large scale clinical datasets Interpretation
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More informationEffect of short- and long-acting inhaled β 2 -agonists on exhaled nitric oxide in asthmatic patients
Eur Respir J 1997; 10: 1483 1488 DOI: 10.1183/09031936.97.71483 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of short- and long-acting
More informationLung Function and Sputum Characteristics of Patients with Severe Asthma During an Induced Exacerbation by Double-Blind Steroid Withdrawal
Lung Function and Sputum Characteristics of Patients with Severe Asthma During an Induced Exacerbation by Double-Blind Steroid Withdrawal JOHANNES C. C. M. in t VEEN, HERMELIJN H. SMITS, PIETER S. HIEMSTRA,
More informationEffect of Inhaled Corticosteroids on Bronchial Hyperresponsiveness in Patients with Mild Asthma
2 3 ai.r. 259 Asian Pacific Journal of Allergy and Immunology (1995) 13 : 81-85 Effect of Inhaled Corticosteroids on Bronchial Hyperresponsiveness in Patients with Mild Asthma Somkiat Wongtim, Somkld Mogmued,
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationNeutrophils in induced sputum arise from central airways
Eur Respir J 2000; 15: 36±40 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Neutrophils in induced sputum arise from central airways Y.P.
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationInduced sputum in childhood asthma
AM Li TWT Tsang DFY Chan RYT Sung TF Fok MEDICAL PRACTICE Induced sputum in childhood asthma!"#$%& Asthma is characterised by variable degrees of airway obstruction, airway hyper-responsiveness, and chronic
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationEffect of Inhaled Budesonide on Lung Function and Airway Inflammation Assessment by Various Inflammatory Markers in Mild Asthma
Effect of Inhaled Budesonide on Lung Function and Airway Inflammation Assessment by Various Inflammatory Markers in Mild Asthma SAM LIM, ANON JATAKANON, MATTHIAS JOHN, THOMAS GILBEY, BRIAN J. O CONNOR,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationOptimal asthma control, starting with high doses of inhaled budesonide
Eur Respir J 2; 16: 226±235 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 Optimal asthma control, starting with high doses of inhaled H.K.
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationT he development of tolerance following the use of long
662 ASTHMA Cross tolerance to salbutamol occurs independently of b 2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol D K C Lee, C M Jackson, C E Bates, B J Lipworth...
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationNON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS. J. Sastre. Allergy Service
NON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS J. Sastre. Allergy Service Asthma: definition Asthma is a syndrome defined on basis of three main aspects: 1- Symptoms due to variable and reversible airway obstruction
More information), the dose of histamine required to provoke a fall in FEV 1. of more than 20% (PD 20
Thorax 1999;54:103 107 103 Pulmonology, Isala Clinics/Weezenlanden Hospital, 00 GM Zwolle, The P L P Brand Pulmonology, Juliana The Hague, The E J Duiverman Pulmonology, Beatrix Groningen, The H J Waalkens
More informationBenzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma
The Korean Journal of Internal Medicine : 22:244-248, 2007 Benzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma Byoung Hoon Lee, M.D. and Sang-Hoon Kim, M.D. Department
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationPerforming a Methacholine Challenge Test
powder for solution, for inhalation Performing a Methacholine Challenge Test Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2016. All rights reserved. Healthcare professionals
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationFormoterol used as needed in patients with intermittent or mild persistent asthma
Respiratory Medicine (2005) 99, 461 470 Formoterol used as needed in patients with intermittent or mild persistent asthma Alexandr Chuchalin a, Milan Kasl b, Thomas Bengtsson c,, Ulf Nihlen c, Johan Rosenborg
More informationEffect of disease duration on dose response of inhaled budesonide in asthma
Respiratory Medicine (2008) 102, 1065 1072 Effect of disease duration on dose response of inhaled budesonide in asthma Olof Selroos a,b, a Mjölbolsta Hospital, Karis, Finland b SEMECO AB, Skogsvägen 5,
More informationBeta 2 adrenoceptor agonists and the Olympic Games in Athens
Beta 2 adrenoceptor agonists and the Olympic Games in Athens 1 Appendix A of the Olympic Movement Anti-Doping Code, the List of Prohibited Substances and Prohibited Methods dated 1 st January 2003 states
More informationAirway calibre as a confounder in interpreting
702 Medical Department TTA 7511, State University Hospital, Copenhagen, Denmark A Dirksen F Madsen T Engel L Frolund J H Heing H Mosbech Reprint requests to: Dr A Dirksen, Department of Pulmonary Medicine
More informationMild Exacerbations and Eosinophilic Inflammation in Patients With Stable, Well-Controlled Asthma After 1 Year of Follow-up*
Mild Exacerbations and Eosinophilic Inflammation in Patients With Stable, Well-Controlled Asthma After 1 Year of Follow-up* Jose Belda, MD, PhD; Jordi Giner, RN; Pere Casan, MD, PhD; and Joaquin Sanchis,
More informationReproducibility of measurements of exhaled NO, and cell count and cytokine concentrations in induced sputum
Eur Respir J 2; 16: 242±246 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 Reproducibility of measurements of exhaled NO, and cell count and
More informationChronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines
Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis ACCP Evidence-Based Clinical Practice Guidelines Christopher E. Brightling, MBBS, PhD, FCCP Objectives: Nonasthmatic eosinophilic bronchitis is
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationLeukotriene C 4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 2003? 2003564422426Original ArticleLeukotriene C4 synthasej. J. Lima et al. Leukotriene C 4 synthase
More informationImproved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Eur Respir J 2001; 18: 262 268 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Improved asthma control with budesonide/formoterol in a single
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationSeasonal Factors Influencing Exercise-Induced Asthma
Original Article Allergy Asthma Immunol Res. 2012 July;4(4):192-198. http://dx.doi.org/10.4168/aair.2012.4.4.192 pissn 2092-7355 eissn 2092-7363 Seasonal Factors Influencing Exercise-Induced Asthma Inseon
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationClinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids
Eur Respir J 1998; 12: 1099 1104 DOI: 10.1183/09031936.98.12051099 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1998 European Respiratory Journal ISSN 0903-1936 Clinical efficacy of low-dose
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationAdenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma
Respiratory Medicine (2004) 98, 651 655 Adenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma E. Bucchioni, Z. Csoma, L. Allegra, K.F. Chung, P.J. Barnes, S.A. Kharitonov*
More informationYoung Yoo, MD; Jinho Yu, MD; Do Kyun Kim, MD; and Young Yull Koh, MD
Original Research ASTHMA Percentage Fall in FVC at the Provocative Concentration of Methacholine Causing a 20% Fall in FEV 1 in Symptomatic Asthma and Clinical Remission During Adolescence* Young Yoo,
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationAsthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
More informationLack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma
Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma HAROLD S. NELSON, ROBERT B. BERKOWITZ, DAVID A. TINKELMAN, AMANDA H. EMMETT, KATHLEEN A. RICKARD, and STEVEN
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationresponsiveness in asthmatic patients and smokers
63 Department of Pulmonology B Auffarth D S Postma G H Koeter Th W van der Mark Department of Allergology J G R de Monchy University Hospital, 973 EZ Groningen, The Netherlands Reprint requests to: Professor
More informationAirway Hyperresponsiveness to Hypertonic Saline as a Predictive Index of Exercise-Induced Bronchoconstriction
The Korean Journal of Internal Medicine: 20:284-289, 2005 Airway Hyperresponsiveness to Hypertonic Saline as a Predictive Index of Exercise-Induced Bronchoconstriction Inseon S. Choi, M.D., Se-Woong Chung,
More informationAlternative agents for anti-inflammatory treatment of asthma
Alternative agents for anti-inflammatory treatment of asthma Stanley J. Szefler, MD, a,b and Harold S. Nelson, MD, c Denver, Colo Recent guidelines for the management of asthma have emphasized the role
More informationInfluence of Beclomethasone and Salmeterol on the Perception of Methacholine-Induced Bronchoconstriction*
Influence of Beclomethasone and Salmeterol on the Perception of Methacholine-Induced Bronchoconstriction* Louis-Philippe Boulet, MD, FCCP; Helene Turcotte, MS; Andre Cartier, MD; Joanne Milot, BS; Johanne
More informationD N R Payne, N M Wilson, A James, H Hablas, C Agrafioti, A Bush
Thorax 2001;56:345 350 345 Original articles Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK DNRPayne N M Wilson A James H Hablas C Agrafioti A
More informationRelationship between Methacholine Challenge Testing and exhaled Nitric Oxide in adult patients with suspected bronchial asthma
O R I G I N A L A R T I C L E S Eur Ann Allergy Clin Immunol Vol 46, N 3, 109-113, 2014 M. Giovannini, M. Valli, V. Ribuffo, R. Melara, G. Cappiello, E. Businarolo, A. Andreani Relationship between Methacholine
More information